 Synlogic Inc NASDAQ: SYBX has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria PKU. PKU is a rare genetic disease that manifests at birth and is characterized by an inability to break down phenylalanine, an amino acid commonly found in many foods. 